PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperphosphatemia |
| Phenotype | C0035078|renal failure |
| Sentences | 11 |
| PubMedID- 24975675 | Ferric citrate hydrate (jtt-751) is being developed as a treatment for hyperphosphatemia with chronic renal failure and has shown a serum phosphorus-lowering effect in ckd patients. |
| PubMedID- 25817287 | The current therapy for hyperphosphatemia in patients with chronic renal failure consists of dietary pi restriction combined with administration of pi binders, but each therapy has practical problems. |
| PubMedID- 20861618 | The control of hyperphosphatemia in renal failure: between vascular calcification and inflammation. |
| PubMedID- 20486851 | Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. |
| PubMedID- 21468200 | Concomitant hyperphosphatemia, especially in patients with renal failure, requires phosphorus-lowering therapies. |
| PubMedID- 25866250 | hyperphosphatemia is common in patients with chronic renal failure. |
| PubMedID- 21719763 | Methods and results: in adenine-induced renal failure rats with hyperphosphatemia, massive calcification was induced in the aortic media. |
| PubMedID- 21543019 | Conclusion: this study demonstrates a high prevalence of hyperphosphatemia in patients with moderate renal failure. |
| PubMedID- 22798709 | Administration of 0.75% adenine-containing diet for 21 days induced renal failure with hyperphosphatemia, and impaired acetylcholine-dependent vasodilation of thoracic aortic ring in rats. |
| PubMedID- 21595516 | However, calcium citrate, which is also used for supplementation purposes, has not been studied previously and calcium acetate, which is used to treat hyperphosphatemia in renal failure, has been reported to show little or no interference with levothyroxine absorption in a retrospective pharmacoepidemiologic study. |
| PubMedID- 20819513 | Background: hyperphosphatemia in renal failure has been identified as a major role in the pathogenesis of hyperparathyroidism that is independent of changes in serum calcium and 1,25(oh)(2)d(3). |
Page: 1